Fera Requests FDA Orphan Drug Designation for Naproxcinod for SCD

Fera Requests FDA Orphan Drug Designation for Naproxcinod for SCD
1
(1)

Fera Pharmaceuticals submitted an application to the U.S. Food and Drug Administration (FDA) requesting orphan drug status for naproxcinod, a potential treatment for for sickle cell disease (SCD).

Orphan drug designation is given to experimental treatments for rare diseases (those that affect fewer than 200,000 people in the U.S.) to support their development. The designation also comes with certain benefits, including financial incentives for clinical development and commercialization, special fee exemptions, as well as seven-year market exclusivity in the U.S. if granted regulatory approval.

Naproxcinod, originally developed by Nicox, is a non-steroidal anti-inflammatory treatment candidate specifically designed to release nitric oxide (NO), a gas that induces the relaxation and widening of blood vessels.

The experimental medication also is intended to block the activity of cyclooxygenase (COX) — an enzyme involved in the production of pro-inflammatory molecules, including prostaglandins.

With its dual mechanism of action, naproxcinod is expected to lower inflammation caused by the destruction of sickled red blood cells and improve blood flow.

Based on promising data from previous pharmacodynamics studies — studies that assess the effects a medication has on the body — in animal models of SCD, Fera decided to focus the development of naproxcinod on the treatment of vaso-occlusive crises (VOCs). VOCs are the most common complication of SCD caused by the rupture of blood vessels throughout the body.

The company is planning additional studies and other activities in preparation for a clinical trial to evaluate naproxcinod’s effectiveness in SCD patients. The study’s launch is pending on the FDA’s decision to grant orphan drug designation to naproxcinod, Nicox stated in a press release.

Naproxcinod already has been tested as a treatment for osteoarthritis in three completed Phase 3 trials (NCT00504127, NCT00541489, NCT00542555) that enrolled more than 2,700 participants.

In December 2015, Nicox and Fera entered into a collaboration agreement, in which Fera received exclusive rights to develop and commercialize naproxcinod in the U.S.

Under the terms of the agreement, Fera has sole responsibility for the clinical development, manufacturing, regulatory and marketing activities related to naproxcinod in the country. 

In turn, Nicox became eligible to receive $40 million if the annual sales of naproxcinod reach $1 billion for any indication in the U.S. In addition, the company is eligible to receive royalty payments of 7% on the product’s net sales in the country.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 15
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • mitapivat and SCD
  • RMAT designation, CTX001
  • Coronavirus and US reopening
  • APCER report Endari

How useful was this post?

Click on a star to rate it!

Average rating 1 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?